GENOVA Inc. (JP:9341)
:9341
Want to see JP:9341 full AI Analyst Report?
Top Page
GENOVA Inc.
(9341)
Select Model
Select Model
Rating:67Neutral
Price Target:
¥607.00
▲(4.30% Upside)
Action:ReiteratedDate:10/30/25
GENOVA Inc. receives an overall stock score of 67, driven primarily by strong financial performance with robust revenue growth and a stable balance sheet, alongside an attractive valuation with a low P/E ratio and high dividend yield. However, bearish technical indicators reflecting a downward price trend and weak momentum significantly weigh on the score. Investors should monitor profitability margins and cash flow challenges closely.
Positive Factors
Revenue Growth
Consistent revenue growth indicates expanding market reach and successful product adoption, enhancing long-term business sustainability.
Negative Factors
Decline in Net Profit Margin
A declining net profit margin suggests increased expenses or lower operational efficiency, potentially impacting future profitability.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Consistent revenue growth indicates expanding market reach and successful product adoption, enhancing long-term business sustainability.
Read all positive factors
GENOVA Inc. (9341) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥9.83B
Dividend Yield5.3%
Average Volume (3M)127.01K
Price to Earnings (P/E)39.0
Beta (1Y)0.95
Revenue Growth1.32%
EPS Growth-79.33%
CountryJP
Employees352
SectorHealthcare
Sector Strength45
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)3.73
Shares Outstanding17,837,600
10 Day Avg. Volume126,090
30 Day Avg. Volume127,006
Financial Highlights & Ratios
PEG Ratio-0.69
Price to Book (P/B)2.50
Price to Sales (P/S)1.75
P/FCF Ratio16.53
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)157.5
Revenue Forecast (FY)¥15.40B
GENOVA Inc. Business Overview & Revenue Model
Company Description
GENOVA, Inc. engages in the medical platform and smart clinic businesses in Japan. It offers Medical Doc, a platform that distributes articles for medical institutions, patient experience articles, treatment videos, and medical-related articles. I...
How the Company Makes Money
GENOVA Inc. generates revenue through multiple streams, primarily from the sale of its proprietary pharmaceuticals and biologics. The company partners with healthcare institutions and pharmaceutical distributors to market and distribute its produc...
GENOVA Inc. Financial Statement Overview
Summary
Income Statement
75
Positive
Balance Sheet
85
Very Positive
Cash Flow
60
Neutral
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 9.32B | 10.01B | 8.68B | 6.51B | 4.80B | 3.77B |
| Gross Profit | 6.74B | 7.38B | 6.55B | 4.79B | 3.50B | 2.63B |
| EBITDA | 1.34B | 2.11B | 2.38B | 1.79B | 1.09B | 816.44M |
| Net Income | 930.62M | 1.41B | 1.73B | 1.26B | 686.27M | 629.35M |
Balance Sheet | ||||||
| Total Assets | 7.58B | 8.53B | 8.20B | 5.41B | 2.82B | 1.87B |
| Cash, Cash Equivalents and Short-Term Investments | 5.18B | 5.87B | 5.97B | 3.86B | 1.65B | 1.17B |
| Total Debt | 8.33M | 20.84M | 377.78M | 28.25M | 163.50M | 133.42M |
| Total Liabilities | 1.16B | 1.53B | 2.16B | 1.37B | 1.33B | 1.10B |
| Stockholders Equity | 6.41B | 7.00B | 6.04B | 4.04B | 1.49B | 768.35M |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | 1.06B | 1.77B | 1.11B | 513.36M | 1.04B |
| Operating Cash Flow | 0.00 | 1.19B | 1.82B | 1.20B | 623.77M | 1.06B |
| Investing Cash Flow | 0.00 | -275.93M | -94.24M | -113.45M | -179.06M | -68.18M |
| Financing Cash Flow | 0.00 | -1.01B | 376.82M | 1.13B | 59.88M | -75.09M |
GENOVA Inc. Technical Analysis
Positive
582.00
Price Trends
571.05
Positive
565.11
Positive
596.08
Negative
Market Momentum
1.00
Positive
49.99
Neutral
26.67
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:9341, the sentiment is Positive. The current price of 582 is above the 20-day moving average (MA) of 570.10, above the 50-day MA of 571.05, and below the 200-day MA of 596.08, indicating a neutral trend. The MACD of 1.00 indicates Positive momentum. The RSI at 49.99 is Neutral, neither overbought nor oversold. The STOCH value of 26.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:9341.
GENOVA Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
67 Neutral | ¥9.83B | 38.97 | ― | 5.30% | 1.32% | -79.33% | |
63 Neutral | ¥65.67B | 228.03 | ― | 0.39% | 10.70% | ― | |
52 Neutral | ¥7.85B | 33.39 | ― | ― | 25.33% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | ¥73.72B | 77.03 | 5.76% | ― | 25.54% | -64.88% | |
44 Neutral | ¥2.59B | -4.28 | ― | ― | 20.39% | 34.43% |
* Healthcare Sector Average
JP:9341
GENOVA Inc.
551.00
-371.61
-40.28%
JP:4480
Medley
2,252.00
-1,228.00
-35.29%
JP:3902
Medical Data Vision Co.Ltd.
1,684.00
1,250.00
288.02%
JP:4438
Welby Inc.
307.00
-27.00
-8.08%
JP:9218
Mental Health Technologies Co. Ltd.
747.00
-6.29
-0.84%
JP:366A
Wellness Communications Corporation
969.00
-794.59
-45.06%
GENOVA Inc. Corporate Events
GENOVA Inc. Reports Decline in Financial Performance for H1 2025
Nov 13, 2025
GENOVA Inc. reported a decline in its financial performance for the six months ended September 30, 2025, with net sales decreasing by 3.3% compared to the previous year. The company experienced a loss in operating and ordinary profit, as well as a...
GENOVA Inc. Reports Q2 Financial Discrepancies, Maintains Full-Year Forecast
Nov 13, 2025
GENOVA Inc. announced a discrepancy between its forecasted and actual financial results for the second quarter ending September 30, 2025. The company experienced lower-than-expected operating, recurring, and net profits due to additional losses fr...
GENOVA Inc. Updates Disclosure with XBRL Data
Oct 16, 2025
GENOVA Inc. has announced the addition of XBRL data to its disclosure document released on October 15, 2025. This update does not affect the PDF version of the document, indicating no corrections were needed, which suggests the company’s com...
GENOVA Inc. Revises FY3/2026 Forecast Amidst Industry Challenges
Oct 14, 2025
GENOVA Inc. announced a downward revision of its full-year business forecast for FY3/2026 due to slower growth in its medical platform business, impacted by changes in the competitive environment from generative AI technologies. The company plans ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.